DKK3 expression was determined to promote growth of pancreatic ductal adenocarcinoma, metastasis, and resistance to systemic therapies. By targeting the gene in an autochthonous model, researchers were able to stop tumor growth, induce CD3+ and CD8+ T cells, and double survival rates. Read more . . .
An investigational antibody directed against Dickkopf-3 (DKK3) may be the key in suppressing tumor growth and extending survival in patients with pancreatic adenocarcinoma, according to a recent preclinical study published in Science Translational Medicine.